Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 126 - 150 of 1585 in total

Mineral oil

Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced...
Approved
Vet approved
Matched Mixtures name: … Therapeutic Bath Oil ... Therapeutic Skin Lotion …

Apis mellifera venom

Apis mellifera venom is an extract of Apis mellifera venom. Apis mellifera venom is used in allergenic testing.
Approved
Matched Mixtures name: … Bee Venom Specialized Therapeutic …
Matched Categories: … Miscellaneous Therapeutic Agents …

Tipiracil

Tipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been...
Approved
Investigational
Matched Categories: … Narrow Therapeutic Index Drugs ... MATE 1 Substrates with a Narrow Therapeutic Index ... OCT2 Substrates with a Narrow Therapeutic Index …

Pembrolizumab

Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes...
Approved
Matched Categories: … PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors …

Phenelzine

Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
Approved

Glofitamab

Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.[L45698,A258488] Glofitamab was approved...
Approved
Investigational

Sorafenib

Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also...
Approved
Investigational
Matched Categories: … Protein Kinase Inhibitors ... Narrow Therapeutic Index Drugs ... UGT1A9 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index …

Diethylpropion

A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)
Approved
Illicit
Matched Description: … appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic …

Ixazomib

Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to...
Approved
Investigational
Matched Categories: … Narrow Therapeutic Index Drugs ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index …

Tebentafusp

Tebentafusp is a gp100 peptide-HLA-directed CD3 T cell engager. It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism of action. ImmTACs bind to target cancer cells that express a specific antigen of...
Approved
Investigational
Matched Description: … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T …
Matched Categories: … Recombinant Proteins …

Pegfilgrastim

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of developing febrile neutropenia...
Approved
Matched Description: … Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF …

Tralokinumab

Atopic dermatitis (AD) is an inflammatory skin disorder that causes skin inflammation, skin barrier dysfunction, and chronic pruritus. It is estimated to affect up to 20% of adults and children worldwide, and is frequently associated with other atopic conditions such as asthma or allergic rhinitis. While AD is a heterogenous...
Approved
Investigational

Ancestim

Ancestim is a non-glycosylated recombinant methionyl human stem cell factor. It is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine . Ancestim was...
Approved
Investigational
Withdrawn
Matched Description: … Ancestim is a non-glycosylated recombinant methionyl human stem cell factor. ... It is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the …

Nedaplatin

Nedaplatin is a second generation platinum analog . It is less nephrotoxic than DB00515 but has proven equally effective. It was approved for use in Japan in 1995.
Approved
Investigational
Matched Categories: … Narrow Therapeutic Index Drugs ... Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index …

Selumetinib

Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming. However,...
Approved
Investigational
Matched Description: … signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein …
Matched Categories: … Protein Kinase Inhibitors ... Mitogen-activated protein kinase (MEK) inhibitors ... Mitogen-Activated Protein Kinase Kinase 1 Inhibitors ... Mitogen-Activated Protein Kinase Kinase 2 Inhibitors …

Ranibizumab

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration.[A2301, L38978] Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovascular...
Approved
Matched Description: … Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against …

Acenocoumarol

Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase. This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, IX and X, and interferes with coagulation. Hematocrit, hemoglobin, international normalized ratio and liver panel should be monitored. Patients...
Approved
Investigational
Matched Categories: … Narrow Therapeutic Index Drugs ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index …

Medical air

Medical air is supplied by a special air compressor to patient care areas using clean outside air.
Approved
Vet approved
Matched Categories: … Other Miscellaneous Therapeutic Agents …

Tegafur

Tegafur (INN, BAN, USAN) is a prodrug of DB00544 (5-FU), an antineoplastic agent used as the treatment of various cancers such as advanced gastric and colorectal cancers. It is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with DB09257 and DB03209, or along with...
Approved
Investigational
Matched Categories: … Narrow Therapeutic Index Drugs ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index …

Glecaprevir

Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with DB13878, glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic barrier against resistance...
Approved
Investigational
Matched Description: … In combination with [DB13878], glecaprevir is a useful therapy for patients who experienced therapeutic …

Medrogestone

Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. It was conceived as an alternative for an orally effective contraceptive option. It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing. It was never approved by the FDA.
Approved
Withdrawn

Peginterferon alfa-2b

Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most...
Approved
Matched Description: … Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat ... Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by …

Glucarpidase

Glucarpidase is a recombinant carboxypeptidase G2 produced by genetically modified Escherichia coli bacteria. It is a 390-amino acid homodimer protein. High-dose methotrexate, an antifolate agent, has been widely and safely used for many decades in treating various cancers; however, even with aggressive hydration, urine alkalinization, and leucovorin rescue, some patients...
Approved
Investigational
Matched Description: … It is a 390-amino acid homodimer protein. ... Glucarpidase is a recombinant carboxypeptidase G2 produced by genetically modified _Escherichia coli_ ... be cloned into _Escherichia coli_, allowing the enzyme to be produced in sufficient quantities for therapeutic …

Chloramphenicol succinate

Chloramphenicol succinate is an ester prodrug of chloramphenicol. Chloramphenicol is a bacteriostatic antibiotic. Use of chloramphenicol succinate and chloramphenicol has decreased due to the risk of potentially fatal blood dyscrasias. Chloramphenicol succinate was granted FDA approval on 20 February 1959.
Approved
Matched Categories: … Narrow Therapeutic Index Drugs ... P-glycoprotein substrates with a Narrow Therapeutic Index …

Mupirocin

Mupirocin, formerly termed pseudomonic acid A, is a novel antibacterial agent with a unique chemical structure and mode of action apart from other antibiotic agents. Produced by fermentation using the organism Pseudomonas fluorescens, mupirocin is a naturally-occurring antibiotic that displays a broad-specturm activity against many gram-positive bacteria and certain gram-negative...
Approved
Investigational
Vet approved
Matched Description: … [L10580] It primarily works by inhibiting bacterial protein synthesis. ... mupirocin does not demonstrate cross-resistance with other classes of antimicrobial agents, giving it a therapeutic …
Matched Categories: … Protein Synthesis Inhibitors …
Displaying drugs 126 - 150 of 1585 in total